📰 Bridging Therapy News

Bridging Therapy News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Bridging Therapy. Real-time updates on events, politics, business and more.

Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24, 2023

Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.

Translating Recent Evidence Real World Management Refractory Diffuse Largeb Cell Lymphoma Diffuse Largeb Cell Lymphoma Relapsed Refractory Dlbcl Rr Dlbcl

Source: onclive.com

Allogene Therapeutics, Inc.: Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 4, 2023

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused

United States Christine Cassiano Allogene Allo Madeleine Goldstein Zachary Roberts Drug Administration

Source: finanznachrichten.de

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2023

United States Allogene Allo Madeleine Goldstein Zachary Roberts Christine Cassiano American Society Of Clinical Oncology

Source: marketscreener.com

Allogene Therapeutics Presents Updated ALLO-501/501A Phase

June 3, 2023

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to...

United States Madeleine Goldstein Allogene Allo Zachary Roberts Christine Cassiano European Hematology Association

Source: globenewswire.com